CD317+ MSC ,

Jun Song1, Qi Ma1,2,3, Yumeng Li1,2,3

  • 1Key Laboratory of Animal Cellular and Genetic Engineering of Heilongjiang Province, College of Life Science, Northeast Agricultural University, Harbin, 150000, People's Republic of China.

PubMed
概括

介质细胞干/干细胞 (MSCs) 显示出治疗前景,但由于细胞异质性而存在不一致性. 这项研究确定CD317+MSCs是增强免疫抑制的亚群,具有治疗免疫疾病的潜力.